Mitochondrial myopathy-lactic acidosis-deafness syndrome
MONDO:0016825Mitochondrial myopathy-lactic acidosis-deafness is a type of metabolic myopathy described only in two sisters to date, presenting during childhood, and characterized clinically by growth failure, severe muscle weakness, and moderate sensorineural deafness and biochemically by metabolic acidosis, elevated serum pyruvate concentration, hyperalaninemia and hyperalaninuria. There have been no further descriptions in the literature since 1973.
Also known as: mitochondrial myopathy with lactic acidosis, mitochondrial myopathy-lactic acidosis-hearing loss syndrome, MMLA, metabolic myopathy associated with chronic lactic acidemia, growth failure, and nerve deafness
18 clinical trials for this condition and its sub-types, 0 tagged with Mitochondrial myopathy-lactic acidosis-deafness syndrome itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New drug shows promise for rare energy disorder
Disease control CompletedThis study tested a new drug called OMT-28 in 28 people with primary mitochondrial disease, a condition that affects how cells produce energy. Participants took the drug once daily for 6 months, and researchers measured safety, blood markers of inflammation, and symptoms like fat…
Phase 2 • Sponsor: Omeicos Therapeutics GmbH • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Long-Term safety of mitochondrial drug confirmed in 101 patients
Disease control CompletedThis study looked at the safety of vatiquinone in 101 people with inherited mitochondrial disease who had already taken the drug in a previous study or treatment plan. The goal was to track any side effects until the drug became commercially available or the program ended. Partic…
Phase 3 • Sponsor: PTC Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC